SCHEMBL13629279

SCHEMBL13629279

CCc1ccc(NS(=O)(=O)c2cccc(Cl)c2Cl)cc1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PGR P06401 1/20 0.60
ALDH1A1 P00352 5/20 0.57
TP53 P04637 1/20 0.53
UCHL1 P09936 1/20 0.51
PTGES2 Q9H7Z7 2/20 0.50
LMNA P02545 3/20 0.49
HPGD P15428 2/20 0.49
POLB P06746 1/20 0.49
MAPT P10636 1/20 0.49
XBP1 P17861 1/20 0.49
HTT P42858 1/20 0.49
MEN1 O00255 1/20 0.48
THRB P10828 1/20 0.48
KMT2A Q03164 1/20 0.48
SGK1 O00141 1/20 0.48
IDH1 O75874 1/20 0.48
GAA P10253 1/20 0.48
PKLR P30613 1/20 0.47
CCR4 P51679 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13853017 0.88 ALDH1A1 (0.68) PGRALDH1A1TP53UCHL1LMNA
SCHEMBL13875335 0.83 PGR (0.65) PGRALDH1A1PTGES2LMNAHPGD
SCHEMBL13852948 0.83 ALDH1A1 (0.61) PGRALDH1A1PTGES2LMNAHPGD
SCHEMBL4160594 0.82 PGR (0.56) PGRALDH1A1PTGES2LMNAHPGD
SCHEMBL10455160 0.81 PGR (0.75) PGRALDH1A1PTGES2SGK1PKLR
SCHEMBL13629401 0.81 ALDH1A1 (0.65) PGRALDH1A1PTGES2LMNAHPGD
SCHEMBL17483805 0.81 PGR (0.62) PGRALDH1A1PTGES2LMNAHPGD
SCHEMBL13615019 0.81 PGR (0.62) PGRALDH1A1PTGES2LMNAHPGD
SCHEMBL95664 0.80 PGR (0.65) PGRALDH1A1PTGES2LMNAHPGD
SCHEMBL13629312 0.80 ALDH1A1 (0.58) PGRALDH1A1PTGES2LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK PGR 1506/4885ALDH1A1 2057/4885TP53 1988/4885
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK PGR 1648/4885ALDH1A1 2121/4885TP53 2031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.